U.S. markets open in 28 minutes

Teligent, Inc. (TLGT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.1735-0.0279 (-13.85%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2014
Bid0.1718 x 900
Ask0.1729 x 1000
Day's Range0.1650 - 0.2090
52 Week Range0.0200 - 1.6000
Avg. Volume7,713,498
Market Cap16.104M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-2.1010
Earnings DateDec 29, 2021 - Jan 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TLGT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teligent, Inc.
    Daily Spotlight: Another Reduction to Argus' 3Q GDP ForecastData that has emerged in recent weeks illustrates that the economy is still expanding, though some white-hot growth rates in certain sectors are starting to cool. The primary driver of GDP over the next few quarters is likely to be the country's physical health, as the nation recovers from the COVID-19 pandemic. Trends here have been slightly more positive in recent weeks, as the fourth wave of the pandemic, due largely to the Delta variant of COVID-19, may be past its peak. The domestic employment environment is in better shape than it was a year ago, though still far from full strength -- and it has weakened recently due to the Delta variant. Auto sales have recovered, but inventories are low due to bottlenecks. And the housing market, which had been strong in 1H21, is starting to cool as house prices soar. Rolling all the data up, and taking into account rising COVID cases as well as emerging supply chain issues and inventory levels, our GDP model now calls for 4.2% increase in GDP in 3Q21. We expect better growth in 4Q, too, before rates fall somewhat more sharply in 2022. On an annual basis, we look for overall GDP growth of approximately 5.8% in 2021 and 3.7% in 2022. Our estimates are consistent with consensus forecasts and the outlook from the Federal Reserve, which call for growth of 4%-6% in 2021. The GDPNow Forecast from the Federal Reserve Bank of Atlanta is 3.2% for 3Q21.
    Fair Value
    Economic Moat
    16 days agoArgus Research
View more
  • Benzinga

    22 Stocks Moving in Friday's Pre-Market Session

    Gainers LM Funding America, Inc. (NASDAQ: LMFA) rose 39.5% to $4.80 in pre-market trading after declining around 15% on Thursday. The company recently announced it purchased an additional 4,000 S19J Pro Antminer Machines for a price of $25.3 million to further expand the company's mining capabilities. ABVC BioPharma, Inc. (NASDAQ: ABVC) rose 24.4% to $3.06 in pre-market trading after gaining around 5% on Thursday. ABVC BioPharma recently restructured its joint venture with Lucida. Avadel Pharmac

  • American City Business Journals

    Generic drug maker Teligent files for bankruptcy protection, explores sale of the company

    South Jersey specialty generic pharmaceutical firm Teligent Inc. filed for voluntarily bankruptcy protection on Thursday as it pursues the sale of the company or its core assets. Teligent Inc. of Buena in Atlantic County also said it is arranging for $12 million debtor-in-possession financing from its senior secured lenders. The company also announced that CEO Tim Sawyer and Philip Yachmetz, Teligent's chief legal officer and executive vice president, resigned effective Oct. 8.

  • PR Newswire

    Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

    Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company.